Download the Notable Articles of 2025: nej.md/3L4ot87 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule GLP-1 receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with early type 2 diabetes
Free radicals, stress, current lifestyle of young busy people, rush, and lack of physical activity expose our body to damage and accelerate the ageing process
Are you looking for GLP-1 meal ideas that taste great while helping you meet your weight loss goals
In April 2026, Nora Volkow and Xu reviewed reports of lower rates of alcohol-related events, reduced opioid overdose risk, and associations extending to nicotine, cocaine, cannabis, and other substances
(3) the DSNP's guidelines, expertise, and training approach for the SNP provider network
100 %